Recent genome wide association studies (GWAS) have identified a locus on chromosome 11p15.5, closely associated with serine/threonine kinase 33 (STK33), to be associated with body mass. STK33, a relatively understudied protein, has been linked to KRAS mutation-driven cancers and explored as a potential antineoplastic drug target. The strongest association with body mass observed at this loci in GWAS was rs4929949, a single nucleotide polymorphism located within intron 1 of the gene encoding STK33. The functional implications of rs4929949 or related variants have not been explored as of yet. We have genotyped rs4929949 in two cohorts, an obesity case-control cohort of 991 Swedish children, and a cross-sectional cohort of 2308 Greek school children. We found that the minor allele of rs4929949 was associated with obesity in the cohort of Swedish children and adolescents (OR = 1.199 (95%CI: 1.002–1.434), p = 0.047), and with body mass in the cross-sectional cohort of Greek children (β = 0.08147 (95% CI: 0.1345–0.1618), p = 0.021). We observe the effects of rs4929949 on body mass to be detectable already at adolescence. Subsequent analysis did not detect any association of rs4929949 to phenotypic measurements describing body adiposity or to metabolic factors such as insulin levels, triglycerides and insulin resistance (HOMA).
Citation: Rask-Andersen M, Moschonis G, Chrousos GP, Marcus C, Dedoussis GV, Fredriksson R, et al. (2013) The STK33-Linked SNP rs4929949 Is Associated with Obesity and BMI in Two Independent Cohorts of Swedish and Greek Children. PLoS ONE 8(8): e71353. https://doi.org/10.1371/journal.pone.0071353
Editor: Balraj Mittal, Sanjay Gandhi Medical Institute, India
Received: February 14, 2013; Accepted: June 30, 2013; Published: August 15, 2013
Copyright: © 2013 Rask-Andersen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by the Swedish Research Council, Brain Research Foundation, Novo Nordisk Foundation, Tore Nilsons foundation and Åhlens foundation. R.F. was supported by the Göran Gustafsson foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Over the past 30 years, obesity has become one of the world’s leading health concerns. A recent report by the OECD observed overweight and obesity to have reached high enough proportions in the industrialized parts of the world to be classified as a global epidemic . The rise in prevalence of obesity and overweight is alarming as high BMI is associated with increased risk of developing complex diseases such as cardiovascular disease, type 2 diabetes, cancer etc. Particularly alarming is the rise in childhood obesity observed in industrialized nations, reaching as high as 16.9% among children in the United States (2008) (http://www.cdc.gov). BMI has a high heritability in twin studies and, during the last two decades, monogenic causes have been determined, e.g. loss of function mutations within the leptin-, and leptin receptor gene, as well as melanocortin 4 receptor (reviewed by Farooqi and O’Rahilly ). The genetic influence on weight development is generally more complex however, as has been revealed by genome wide association studies. Large-scale meta-analysis of genome wide association data performed by the GIANT-consortium studies have so far identified at least 32 genetic loci associated with control of body mass development –. While the most powerfully associated obesity-related loci in this study, such as those related to FTO and TMEM18, have been consistently replicated in independent cohorts , the effects of other loci have, as of yet, not been consistently reported in independent cohorts. Replication in more specialized cohorts also allows for secondary analysis to discern specific physiological effects of the associated loci or even identification of other associated traits.
Genetic variants within, and in the proximity of, serine/threonine-protein kinase 33 (STK33) were found to be associated to body weight by the GIANT consortium in 2010 . A single nucleotide polymorphism (SNP), rs4929949, located within intron 1 of STK33, gave the strongest signal in association tests to body mass, but several other SNPs spanning a locus of ∼200 kb, including the entire STK33 gene as well as the proximal upstream area, were also strongly associated . Rs4929949 is a high-frequency SNP with a reported minor allele frequency of about 46% (http://www.1000genomes.org), which makes it suitable for replication in smaller independent cohorts. STK33 is located in a gene-rich region on chromosome 11p15.4 in close proximity to TRIM66 (tripartite motif-containing protein 66), RPL27A (60S ribosomal protein L27a) and ST5 (suppressor of tumorigenicity 5), which are all located within 200 k bp of rs4929949 (Figure 1). Rs4929949 is also located ∼500 kb downstream from the gene encoding TUB (Tubby protein homolog), which has been linked to body weight and obesity in mouse studies  as well as early genetic studies –, but remains unconfirmed in GWAS. As of yet, no functional data exists linking any of the genes in proximity of rs4929949, or rs4929949 itself, to body weight.
Haplotype blocks were visualized in Haploview according to confidence intervals as described by Gabriel et al. . The haplotype block containing rs4929949 is visualized in green. DNA elements from the Encyclopedia of DNA Elements (ENCODE) were visualized via the UCSC genome browser (htytp://genome.ucsc.edu/). Probable regulatory sites are indicated by acetylation of Lysine 27 on Histone H3 (H3K27ac), DNase sensitivity clusters and chromatin immunoprecipitation sequencing results (ChIP-seq).The haplotype block encompasses one probable regulatory element near the 3′ region of STK33 and lies proximally to an additional upstream regulatory element.
In this study, we investigated the association of rs4929949 to obesity and related phenotypes in two independent European cohorts of children and young adolescents from Sweden and Greece.
Materials and Methods
991 children and adolescents comprising two study groups from the Stockholm area were genotyped for rs4929949 (Table 1). These children comprise a case group of 473 obese children and adolescents enrolled at the National Childhood Obesity Centre at Karolinska University Hospital, as well as 518 healthy Swedish adolescents as controls recruited from secondary schools in the Stockholm area. Healthy controls were recruited via school nurses. Chronically ill, obese or overweight were removed from the controls. Siblings were also removed from analysis to reduce bias. Informed written consent was provided by all participants or by their legal guardians (Table 1). Genomic DNA was extracted from peripheral blood using the QiaGen Maxiprep kit (QiaGen, Hilden, Germany). DNA was stored at −20°C until further processing and genotyping.
Cohort of Greek Children and Adolescents – the Healthy Growth Study
2308 Greek school children and adolescents, 1163 males and 1145 females aged 9–13 years, from a wider region of Athens Greece were genotyped (Table 1). These children were participants of the ‘Healthy Growth Study’, a cross-sectional study on health and behavioral indices of primary schoolchildren living in different parts of Greek territory, initiated in 2007 –. Parents were informed via an extended letter describing the aims of the study. Parental consent was given via a signed consent form. Body weight and height was measured using standard procedures and equipment as part of a school-based health and nutrition education program. BMI-z-score was calculated according to the Obesity Task Force (IOTF) definitions . Stage of pubertal development, i.e. Tanner stage , was evaluated by experienced pediatricians via physical examination. Blood samples were obtained after overnight fasting and centrifuged at 3000 rpm for 15 min. Aliquots were stored at −80°C until further processing. Plasma glucose was determined with a enzymatic colorimetric assay (Roche Diagnostics, Visalia, Switzerland). Serum insulin was determined with a chemiluminescence immunoassay (Kyowa Medex Ltd, Minami-Ishiki, Japan).
The study on the Swedish cohort of children and adolescents was approved by the Regional Committee of Ethics, Stockholm (Regionala etikprövningsnämnden, Stockholm). Approval to conduct the study in Greek schools was granted by the Greek Ministry of National Education while ethical approval for the study was granted by the ethics committee of the Harokopio University. Written consent was obtained from all participants or their legal guardians.
Genotyping of rs4929949 was carried out with a pre-designed Taqman single-nucleotide polymorphism genotyping assay (Applied Biosystems, Foster City, USA) and an ABI7900 genetic analyzer with SDS 2.2 software at the Uppsala Genome Center (http://www.genpat.uu.se/node462). The genotype call rate was 98.3% in the Swedish cohort and 99.7% in the Greek cohort. Tests for deviation from Hardy-Weinberg equilibrium were performed using a Markov chain Monte Carlo test  in PLINK v1.07 . No deviations from Hardy-Weinberg equilibrium were detected for rs4929949 in the Swedish and Greek cohorts.
Statistical analysis was performed in PLINK v1.07 . Logistic regression was used in the cohort of Swedish children to test association of rs4929949 with obesity. Gender effect was included in the model. Linear regression was used to test association of rs4929949 with BMI z-score and phenotypic measurements in the cohort of Greek children; the model was corrected for gender and pubertal development. A p-value <0.05 was considered significant for association of rs4929949 with obesity in the Swedish cohort and BMI z-score in the Greek cohort. Analysis was also performed in PLINK to detect eventual gender-specific effect. We also tested for a recessive model of the effects of rs4929949 in PLINK.
Power analysis was performed in CaTS power calculator  (http://www.sph.umich.edu/csg/abecasis/CaTS/) and Quanto (http://hydra.usc.edu/gxe/). In the cohort of Swedish adolescents, we had 45% power to detect an association of rs4929949 with obesity at the risk observed in our study at nominal levels of significance (p<0.05), 3% prevalence of childhood obesity in Sweden  and assuming an additive model. For the cohort of Greek children we had 72.4% power to detect an association of rs4929949 with BMI at the observed β-value of 0.08147 for the minor allele, assuming an additive model and nominal thresholds for significance (p<0.05).
To visualize haplotype blocks co-inherited factors associated with rs4929949, we utilized Haploview 4.2 (www.broadinstitute.org/haploview/haploview)  to generate a graphical representation of the linkage disequilibrium (LD) structures from r2 scores. HapMap data version 3, release 27 and data from Utah residents with northern and western European ancestry (CEU) combined with “Toscani in Italia” (TSI) was used to generate the linkage disequilibrium (LD) pattern.
In the Swedish cohort, the minor allele frequency (C-allele) was 50% in obese children and 45.5% in the control population (Table 2). The minor allele frequency in the Greek cohort was 35.8%, which differs from the Swedish cohort and is also somewhat lower than European populations in general (Table 3). This allele frequency is instead more similar to African populations such as Americans of African ancestry in SW USA (ASW) (MAF = 38%, n = 61) and Luhya in Webuye, Kenia (LWK) (MAF = 30%, n = 97), as reported by the 1000 genomes project (http://www.ncbi.nlm.nih.gov/SNP). No deviation from Hardy-Weinberg equilibrium was observed in the Greek cohort, and the observed difference in allele frequency in our study was assumed to be due to natural variation specific to that population.
Rs4929949 is Associated with Clinical Obesity in the Cohort of Swedish Children and with BMI in a Cross-sectional Cohort of Greek Children and Adolescents
We observe the minor allele of rs4929949 to be associated with obesity in the cohort of children from the Stockholm area (OR = 1.199; 95% CI = 1.002–1.434; p = 0.047) (Table 2). The minor allele of rs4929949 was also observed to be associated with higher BMI in the cohort of Greek children (β = 0.08147; p = 0.033) (Table 3). Analysis of secondary phenotypic measurement like insulin sensitivity (HOMA), daily caloric intake, serum cholesterol, triglycerides and measurements describing body adiposity failed to reveal any associations with rs4929949 (Table S1). Association of rs4929949 with several measurements describing body adiposity were observed at the nominal significance level, as well as a trend towards association with insulin levels which was directionally consistent with non-significant effects reported by Speliotes et al. , but only when BMI was not included in the model, indicating these effects to be secondary to the effect of rs4929949 on body weight. No gender-specific effects were observed in either cohort. If we assume a recessive model, we also observe an effect of the minor allele of rs4929949 on body weight in the cohort of Greek children and adolescents (p = 0.015) (Figure 2).
Rs49299492 is Located in a 47 kb Haplotype Block Encompassing the 3′- and Proximal Upstream Region of STK33
Visualisation of linkage disequilibrium using Haploview reveals rs4929949 to be located within a 47 kb haplotype block spanning from within intron 1 to about 10 kb upstream of STK33 (Figure S1). Visualization of regulatory elements within this region via the encyclopedia of DNA elements (ENCODE), revealed the haplotype block to encompass one probable regulatory site with strong signals of occupancy for upstream regulatory factor 1 (USF-1). This haplotype block is also proximal to a probable regulatory binding site for transcriptional repressor CTCF, CCAAT/enhancer-binding protein beta (CEBPB) and transcription factors c-Jun and Jun-D (Figure 1).
We found that rs4929949 was associated with obesity and body mass development in two independent European cohorts of children and adolescents. The observed effects were directionally consistent with reports from the GIANT consortium. Subsequent analysis of effects of rs4929949 on metabolic factors and body adiposity-related phenotypic measurements failed to reveal any statistically significant association in our cohorts. Effects on body adiposity and insulin levels directionally consistent with reports from the GIANT-consortium , were observed when BMI was not included in linear models for association, indicating these effects to be secondary to the effects of rs4929949 on body mass. The effect-sizes that can be observed in our study are of course limited due to the relatively small size of the cohorts. Linkage disequilibrium analysis and ENCODE data revealed one potential regulatory site within the same haplotype block as rs4929949, in the 3′ region of STK33 and one more regulatory site immediately upstream (Figure 1). A possible limitations to our study is the possibility of stratification effects in the Swedish and Greek cohorts as ethnical background was not considered in the recruitment or in the analysis. The recruiting was performed indiscriminately with the aim to reflect the general population and not specific ethnical groups. To minimize potential bias, the control group for the Swedish cohort was recruited from schools in the same region.
Although STK33 has not been directly associated with body mass regulation previously, it is of particular interest because of its potential involvement in GTPase KRas (KRAS) driven cancers and the fact that STK33 has also been targeted pharmacologically. STK33 was first discovered and classified as a serine/threonine-protein kinase putatively related to the Ca2+/calmodulin-dependent kinase-family (CAMK) in 2001  and later observed to preferentially be expressed in testes and lung  and to target the cytoskeletal protein vimentin for phosphorylation . Although the normal functional role of STK33 has yet to be determined, a synthetic lethality RNA interference-screen identified a dependency between STK33 and the KRAS oncogene . KRAS is one of the most frequently activated oncogenes found in about 17–25% of tumor cells . Despite this high prevalence pharmacological means to inhibit KRAS have yet to emerge. Small molecule inhibition of STK33 in vitro did not show sufficient effect on cancer cell-viability, however, leading the authors to speculate on an interaction between mutant KRAS and STK33 independent of its kinase activity .
In conclusion, we found that rs4929949 was associated with body mass and obesity in two cohorts of European children and adolescents showing the effects of this locus to be observable already at adolescence. Effects were consistent with previous large scale GWA-studies for body mass reported by the GIANT-consortium . Rs4929949 is located within intron 1 of the gene encoding STK33, a pharmacologically targeted serine/threonine kinase reported to be involved in KRAS-mediated cancers.
Visualization of haplotype blocks within the STK33-encoding region on chromosome 11 of the human genome. Haploview 4.2 (www.broadinstitute.org/haploview/haploview) was used  to generate a graphical representation of the linkage disequilibrium (LD) structures from r2 scores. HapMap data version 3, release 27 and data from Utah residents with northern and western European ancestry (CEU) combined with “Toscani in Italia” (TSI) was used to generate the linkage disequilibrium (LD) pattern. The rs4929949-containing haplotype block is highlighted in red.
The SNP genotyping was performed by the SNP Technology Platform, Uppsala, Sweden (http://www.genotyping.se) with support from Uppsala University and the Knut and Alice Wallenberg foundation and at the Uppsala Genome Centre. We thank research coordinator Märta Fredriksson and research nurse Micaela Forssén for excellent work with the collection of normal weight adolescents. We thank the Healthy Growth Study Group for their contribution in this study. The Healthy Growth Study Group consists of (1) Harokopio University Research Team/Department of Nutrition and Dietetics: Yannis Manios (Coordinator), George Moschonis (Project manager), Katerina P Skenderi, Evangelia Grammatikaki, Odysseas Androutsos, Sofia Tanagra, Alexandra Koumpitski, Paraskevi-Eirini Siatitsa, Anastasia Vandorou, Aikaterini-Efstathia Kyriakou, Vasiliki Dede, Maria Kantilafti, Aliki-Eleni Farmaki, Aikaterini Siopi, Sofia Micheli, Louiza Damianidi, Panagiota Margiola, Despoina Gakni, Vasiliki Iatridi, Christina Mavrogianni, Kelaidi Michailidou, Aggeliki Giannopoulou, Efstathoula Argyri, Konstantina Maragkopoulou, Maria Spyridonos, Eirini Tsikalaki, Panagiotis Kliasios, Anthi Naoumi, Konstantinos Koutsikas, Katerina Kondaki, Epistimi Aggelou, Zoi Krommyda, Charitini Aga, Manolis Birbilis, Ioanna Kosteria, Amalia Zlatintsi, Elpida Voutsadaki, Eleni-Zouboulia Papadopoulou, Zoi Papazi, Maria Papadogiorgakaki, Fanouria Chlouveraki, Maria Lyberi, Nora Karatsikaki-Vlami, Eva Dionysopoulou and Efstratia Daskalou (2) Aristotle University of Thessaloniki/School of Physical Education and Sports Sciences: Vassilis Mougios, Anatoli Petridou, Konstantinos Papaioannou, Georgios Tsalis, Ananis Karagkiozidis, Konstantinos Bougioukas, Afroditi Sakellaropoulou and Georgia Skouli. (3) University of Athens/Medical School: George P Chrousos, Maria Drakopoulou and Evangelia Charmandari.
Conceived and designed the experiments: RF HBS GM GPC CM GVD. Performed the experiments: MRA GM CM GVD. Analyzed the data: MRA. Contributed reagents/materials/analysis tools: GM GPC CM GVD. Wrote the paper: MRA.
- 1. OECD (2010) Obesity and the Economics of Prevention: Fit not Fat.
- 2. Farooqi IS, O’Rahilly S (2005) Monogenic obesity in humans. Annu Rev Med 56: 443–458.
- 3. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, et al. (2010) Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 42: 937–948.
- 4. Willer CJ, Speliotes EK, Loos RJ, Li S, Lindgren CM, et al. (2009) Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 41: 25–34.
- 5. Jacobsson JA, Schioth HB, Fredriksson R (2012) The impact of intronic single nucleotide polymorphisms and ethnic diversity for studies on the obesity gene FTO. Obes Rev 13: 1096–1109.
- 6. Prada PO, Quaresma PG, Caricilli AM, Santos AC, Guadagnini D, et al. (2013) Tub has a key role in insulin and leptin signaling and action in vivo in hypothalamic nuclei. Diabetes 62: 137–148.
- 7. Shiri-Sverdlov R, Custers A, van Vliet-Ostaptchouk JV, van Gorp PJ, Lindsey PJ, et al. (2006) Identification of TUB as a novel candidate gene influencing body weight in humans. Diabetes 55: 385–389.
- 8. Snieder H, Wang X, Shiri-Sverdlov R, van Vliet-Ostaptchouk JV, Hofker MH, et al. (2008) TUB is a candidate gene for late-onset obesity in women. Diabetologia 51: 54–61.
- 9. Moschonis G, Tanagra S, Vandorou A, Kyriakou AE, Dede V, et al. (2010) Social, economic and demographic correlates of overweight and obesity in primary-school children: preliminary data from the Healthy Growth Study. Public Health Nutr 13: 1693–1700.
- 10. Jacobsson JA, Rask-Andersen M, Riserus U, Moschonis G, Koumpitski A, et al. (2012) Genetic variants near the MGAT1 gene are associated with body weight, BMI and fatty acid metabolism among adults and children. Int J Obes (Lond) 36: 119–129.
- 11. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH (2000) Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 320: 1240–1243.
- 12. Tanner JM (1955) Growth at Adolescence. Oxford: Blackwell Scientific.
- 13. Wigginton JE, Cutler DJ, Abecasis GR (2005) A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 76: 887–893.
- 14. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
- 15. Skol AD, Scott LJ, Abecasis GR, Boehnke M (2006) Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 38: 209–213.
- 16. Sjoberg A, Moraeus L, Yngve A, Poortvliet E, Al-Ansari U, et al. (2011) Overweight and obesity in a representative sample of schoolchildren - exploring the urban-rural gradient in Sweden. Obes Rev 12: 305–314.
- 17. Barrett JC (2009) Haploview: Visualization and analysis of SNP genotype data. Cold Spring Harb Protoc 2009: pdb ip71.
- 18. Mujica AO, Hankeln T, Schmidt ER (2001) A novel serine/threonine kinase gene, STK33, on human chromosome 11p15.3. Gene 280: 175–181.
- 19. Mujica AO, Brauksiepe B, Saaler-Reinhardt S, Reuss S, Schmidt ER (2005) Differential expression pattern of the novel serine/threonine kinase, STK33, in mice and men. FEBS J 272: 4884–4898.
- 20. Brauksiepe B, Mujica AO, Herrmann H, Schmidt ER (2008) The Serine/threonine kinase Stk33 exhibits autophosphorylation and phosphorylates the intermediate filament protein Vimentin. BMC Biochem 9: 25.
- 21. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, et al. (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137: 821–834.
- 22. Kranenburg O (2005) The KRAS oncogene: past, present, and future. Biochim Biophys Acta 1756: 81–82.
- 23. Luo T, Masson K, Jaffe JD, Silkworth W, Ross NT, et al. (2012) STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A 109: 2860–2865.
- 24. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. (2002) The structure of haplotype blocks in the human genome. Science 296: 2225–2229.